2
Announcements
Trials
Browse
Landscape
Status
Completed
2
Sponsor Class
OTHER
2
Study Type
Observational
2
Sponsor
Cancer Type
Thoracic
2
Other solid neoplasm
2
Conditions
Neoplasms
15
Papillomavirus Infections
9
Uterine Cervical Neoplasms
7
Pancreatic Neoplasms
6
Breast Neoplasms
6
Ovarian Neoplasms
5
Prostatic Neoplasms
4
Neuroendocrine Tumors
4
Neoplasm Metastasis
4
Myasthenia Gravis
3
Multiple Myeloma
3
Melanoma
3
Lymphoma
3
Lung Neoplasms
3
Autoimmune Diseases
3
Thyroid Diseases
2
Pancreatic Cyst
2
Neuroblastoma
2
Mesothelioma, Malignant
2
Lymphoma, Non-Hodgkin
2
Leukemia, Lymphocytic, Chronic, B-Cell
2
Leukemia, Hairy Cell
2
Leukemia
2
Hematologic Neoplasms
2
Endometrial Neoplasms
2
Carcinoma, Renal Cell
2
Carcinoma, Non-Small-Cell Lung
2
COVID-19
2
Brain Neoplasms
2
Abortion, Spontaneous
2
Interventions
Cisplatin
57
Pemetrexed
46
pembrolizumab
18
Nivolumab
15
Carboplatin
15
Gemcitabine
14
Cyclophosphamide
13
Radiotherapy
10
Drug Therapy
9
atezolizumab
8
Platinum
7
Ipilimumab
7
Doxorubicin
7
durvalumab
6
1,2-diaminocyclohexaneplatinum II citrate
6
tremelimumab
5
sodium thiosulfate
5
Vinorelbine
5
Radiotherapy, Intensity-Modulated
5
Interleukin-2
5
Chemotherapy, Adjuvant
5
Cerebral Decortication
5
sargramostim
4
fludarabine
4
defactinib
4
aldesleukin
4
tumor necrosis factor-alpha, CNGRC fusion protein, human
3
cediranib
3
Photochemotherapy
3
Neoadjuvant Therapy
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Mesothelioma, Malignant
×
Data Collection
×
Clear all
NCT05308966
2025-10-06
MESO-IMMUNE
Groupe Francais De Pneumo-Cancerologie
Completed
204 enrolled
NCT04775446
2022-02-04
MESOIMMUNE
Centre Hospitalier Intercommunal Creteil
Completed
116 enrolled